(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Non-Alcoholic Steatohepatitis pipeline constitutes 100+ key companies continuously working towards developing 150+ Non-Alcoholic Steatohepatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Non-Alcoholic Steatohepatitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis Market.
The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Non-Alcoholic Steatohepatitis treatment therapies with a considerable amount of success over the years.
- Non-Alcoholic Steatohepatitis companies working in the treatment market are Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceutical, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others, are developing therapies for the Non-Alcoholic Steatohepatitis treatment
- Emerging Non-Alcoholic Steatohepatitis therapies such as – GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others are expected to have a significant impact on the Non-Alcoholic Steatohepatitis market in the coming years.
- In January 2023, Madrigal Pharmaceuticals, Inc. announced additional results from the pivotal Phase III MAESTRO-NASH biopsyclinical trial of Resmetirom, a liver-directed selective thyroid hormone receptor agonist. The new MAESTRO-NASH data are being presented at the NASH-TAG Conference
- In August 2022 Madrigal Pharmaceuticals initiated a multi-national, multicenter, double-blind, randomized, placebo-controlled study in participants with well-compensated NASH cirrhosis. Participants will be randomized 3:1 in a blinded manner to receive 80 mg resmetirom or matching placebo given orally once daily in the morning for the duration of the study and until the required number of Composite Clinical Outcome events are achieved
- In January 2021, US Food and Drug Administration cleared the company’s Investigational New Drug application (IND) forTERN-501, a selective thyroid hormone receptor beta, or THR-β, agonist with enhanced metabolic stability and liver distribution, characteristics that are intended to improve safety and efficacy in NASH patients
Non-Alcoholic Steatohepatitis Overview
Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cell.
Get a Free Sample PDF Report to know more about Non-Alcoholic Steatohepatitis Pipeline Therapeutic Assessment
Emerging Non-Alcoholic Steatohepatitis Drugs Under Different Phases of Clinical Development Include:
- GMA-107: Gmax Biopharm
- LBS-009: Lin Biosciences
- MSDC-0602K: Cirius Therapeutics
- ION224: Ionis Pharmaceuticals
- HU 6: Rivus Pharmaceuticals
- VK-1430: Viking Therapeutics
- EDP-305: Enanta Pharmaceuticals
- HTD 1801: HighTide Biopharma
- SRT-015: Seal Rock Therapeutics
- AZD 2693: AstraZeneca
- BI 456906: Boehringer Ingelheim
- ORMD-0801: Oramed Pharmaceutical
- EYP001: ENYO Pharma
- TERN-501: Terns Pharmaceuticals
- Semaglutide: NovoNordisk
- Resmetirom: Madrigal Pharmaceuticals
- Lanifibranor: Inventiva Pharma
Route of Administration
Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
- Small molecule
Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment
- Non-Alcoholic Steatohepatitis Assessment by Product Type
- Non-Alcoholic Steatohepatitis By Stage and Product Type
- Non-Alcoholic Steatohepatitis Assessment by Route of Administration
- Non-Alcoholic Steatohepatitis By Stage and Route of Administration
- Non-Alcoholic Steatohepatitis Assessment by Molecule Type
- Non-Alcoholic Steatohepatitis by Stage and Molecule Type
DelveInsight’s Non-Alcoholic Steatohepatitis Report covers around 150+ pipeline drugs under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Non-Alcoholic Steatohepatitis product details are provided in the report. Download the Non-Alcoholic Steatohepatitis pipeline report to learn more about the emerging Non-Alcoholic Steatohepatitis therapies
Some of the key companies in the Non-Alcoholic Steatohepatitis Therapeutics Market include:
Key companies developing therapies for Non-Alcoholic Steatohepatitis are – Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, AstraZeneca, Inventiva Pharma, Cirius Therapeutics, Inc, Galectin Therapeutics Inc., Galmed Research and Development, Ltd., Zydus Therapeutics Inc., Rivus Pharmaceuticals, Inc., 89bio, Inc., Lipocine Inc., HighTide Biopharma Pty Ltd, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc., CytoDyn, Inc., Terns, Inc., Poxel SA, Enanta Pharmaceuticals, Inc, Kowa Company, Ltd., NorthSea Therapeutics B.V., Merck, NGM Biopharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, Gilead Sciences, Cascade Pharmaceuticals, Inc, Hepion Pharmaceuticals, Inc., Pfizer, Alnylam Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Future Medicine, Boston Pharmaceuticals, MediciNova, Cellaion, Promethera Therapeutics, Viking Therapeutics, Inc., Novo Nordisk A/S, Eccogene, CohBar, Inc., Aligos Therapeutics, Corcept Therapeutics, Altimmune, Inc., Janssen Pharmaceutical K.K., Enanta Pharmaceuticals, Inc, Arrowhead Pharma, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Novo Nordisk A/S, Metacrine, Inc., Hepagene (Shanghai) Co., Ltd., TaiwanJ Pharmaceuticals Co., Ltd, Viking Therapeutics, Inc., LG Chem, Redx Pharma, and others.
Non-Alcoholic Steatohepatitis Pipeline Analysis:
The Non-Alcoholic Steatohepatitis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Steatohepatitis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Steatohepatitis Treatment.
- Non-Alcoholic Steatohepatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Non-Alcoholic Steatohepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Steatohepatitis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Non-Alcoholic Steatohepatitis drugs and therapies
Non-Alcoholic Steatohepatitis Pipeline Market Drivers
- Rise in prevalence, emerging treatment therapies of NASH, growing demand for NASH therapeutics are some of the important factors that are fueling the Non-Alcoholic Steatohepatitis Market.
Non-Alcoholic Steatohepatitis Pipeline Market Barriers
- However, lack of analogs, use of combination therapies, reimbursement issues and other factors are creating obstacles in the Non-Alcoholic Steatohepatitis Market growth.
Scope of Non-Alcoholic Steatohepatitis Pipeline Drug Insight
- Coverage: Global
- Key Non-Alcoholic Steatohepatitis Companies: Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceutical, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others
- Key Non-Alcoholic Steatohepatitis Therapies: GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others
- Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
- Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers
Request for Sample PDF Report for Non-Alcoholic Steatohepatitis Pipeline Assessment and clinical trials
Table of Contents
|1||Non-Alcoholic Steatohepatitis Report Introduction|
|2||Non-Alcoholic Steatohepatitis Executive Summary|
|3||Non-Alcoholic Steatohepatitis Overview|
|4||Non-Alcoholic Steatohepatitis- Analytical Perspective In-depth Commercial Assessment|
|5||Non-Alcoholic Steatohepatitis Pipeline Therapeutics|
|6||Non-Alcoholic Steatohepatitis Late Stage Products (Phase II/III)|
|7||Non-Alcoholic Steatohepatitis Mid Stage Products (Phase II)|
|8||Non-Alcoholic Steatohepatitis Early Stage Products (Phase I)|
|9||Non-Alcoholic Steatohepatitis Preclinical Stage Products|
|10||Non-Alcoholic Steatohepatitis Therapeutics Assessment|
|11||Non-Alcoholic Steatohepatitis Inactive Products|
|12||Company-University Collaborations (Licensing/Partnering) Analysis|
|13||Non-Alcoholic Steatohepatitis Key Companies|
|14||Non-Alcoholic Steatohepatitis Key Products|
|15||Non-Alcoholic Steatohepatitis Unmet Needs|
|16||Non-Alcoholic Steatohepatitis Market Drivers and Barriers|
|17||Non-Alcoholic Steatohepatitis Future Perspectives and Conclusion|
|18||Non-Alcoholic Steatohepatitis Analyst Views|
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Non-Alcoholic Steatohepatitis Market
DelveInsight’s ‘Non-Alcoholic Steatohepatitis-Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Non-Alcoholic Steatohepatitis Epidemiology
DelveInsight’s ‘Non-Alcoholic Steatohepatitis Epidemiology Forecast to 2032′ report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Concussions Market Size | Pruritus Market | Angioedema Market | Blood Gas And Electrolyte Analyzers Market | Human Papilomavirus Market | Neurovascular Devices Market | Pain Management Devices Market | Pressure Ulcers Market Size | Acute Coronary Syndrome Market | Apheresis Market | Arteriotomy Closure Devices Market | Automated External Defibrillators Market | Xerostomia Market | Choroidal Neovascularization Market | Hyperhidrosis Market | Alopecia Market | Contraceptive Devices Market | Ventilator Market | Alopecia Aerata Market | Osteoarthritis Market | Neurostimulation Devices Market | Global Electrophysiology Devices Market | Astigmatism Market | Graves Orbitopathy Market | HPV-Induced Cancers Market | Hypothalamic Obesity Market | Italy healthcare outlook report
Latest Reports by DelveInsight-
scedosporium infection market | autoimmune pulmonary alveolar proteinosis market | rosai-dorfman disease market | sandhoff disease market | b-cell chronic lymphocytic leukemia market | bladder cancer market | trichomoniasis market | bile duct cancer market | resorbable vascular scaffold market | salivary gland infection market | ischemic stroke market | paget’s disease market | ventricular assist devices market | vascular stents market | vascular graft devices market | bladder scanners market | b-cell non-hodgkin lymphoma market | basal cell carcinoma market | birch allergy market | vein illumination devices market
Recent Blog’s By DelveInsight:
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.